Safety, pharmacokinetics and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.

Authors:

Abstract
E16059Background: Trastuzumab combined with chemotherapy is the standard first-line regimen in HER2- overexpression advanced gastric cancer, and there is no established therapy in the second-line setting. RC48-ADC is a novel humanized anti-HER2 antibody conjugated with Monomethyl Auristatin E (MMAE) via a cleavable linker, which has showed high specificity and potency in vivo and in vitro models of gastric cancer and other solid tumors. Methods: This was an open-label, dose-escalation and dose-expansion study in pts with HER2-overexpression (defined as IHC 2+ or 3+) advanced solid cancers. The dose escalation phase was initialed by accelerated titration (0.1 and 0.5 mg/kg) and then switched to 3+3 scheme (1.0, 2.0 and 2.5 mg/kg, Q2W). In dose expansion phase, pts were given at 2.0mg/kg Q2W. Results: As of Jan 29, 2018, 22 pts (21 gastric cancers and 1 breast cancer) in dose escalation (0.1 - 2.5 mg/kg Q2W, n = 19; 2.0 mg/kg Q3W, n = 3) and 14 pts (11 gastric cancers, 2 urothelial cancers and 1 bile duct c...